Combination Antiretroviral Therapy (cART) for PBC
Study Details
Study Description
Brief Summary
Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at unblinding. All patients will be offered an additional 12 months open label therapy. Observational, open label study will be performed in parallel using Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir in liver transplant recipients meeting all entry criteria except for use of immunosuppression.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Primary endpoint:
Change in mean percentage of alkaline phosphatase (ALP) reduction in cART vs. placebo at 6 and 12 months.
Secondary endpoints:
-
Serum biochemistries bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) will be studied as continuous variables.
-
Composite endpoint used for the POISE study [A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis]: (i) reduction of ALP to < 1.67 upper limit of normal, (ii) normalization of bilirubin within upper limit of normal (ULN) and (iii) reduction of ALP by > 15% at 6 and 12 months.
-
Symptomatic evaluation performed using the PBC-40 to assess five symptom domains relating to fatigue, itch, cognitive symptoms, social and emotional symptoms, and other symptoms.
-
Histological change in grade and stage of PBC using the Nakanuma scoring system for a subgroup of patients undergoing liver biopsy [liver biopsy not compulsory for study].
-
Serial human betaretrovirus measurement in peripheral blood and cellular immune response to viral peptides.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets |
Drug: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)
Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
Other Names:
Drug: Raltegravir
Raltegravir (RTF) 600 mg two tablets by mouth once per day
Other Names:
|
| Placebo Comparator: Placebo Identical tablets resembling one Emtricitabine 200mg and Tenofovir Disoproxil 300mg tablet two Raltegravir 600mg tablets |
Drug: Placebo Oral Capsule [CEBOCAP]
Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change in alkaline phosphatase levels [12 months]
Mean changes in alkaline phosphatase levels after 12 months treatment with combination antiretroviral therapy or placebo.
Secondary Outcome Measures
- Serial changes in alkaline phosphatase [Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy]]
Serial changes in alkaline phosphatase levels with combination antiretroviral therapy or placebo.
- Serial changes in ALT [Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy]]
Serial changes in ALT levels with combination antiretroviral therapy or placebo.
- Serial changes in bilirubin [Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy]]
Serial changes in bilirubin levels with combination antiretroviral therapy or placebo.
- Achievement of the composite biochemistry endpoint [6 and 12 months]
(i) reduction of ALP to < 1.67 upper limit of normal, (ii) normalization of bilirubin within ULN and (iii) reduction of ALP by > 15%
- Human Betaretrovirus load in peripheral blood [Evaluation baseline, 3 months, 6 months and end of RCT; then 3 months, 6 monthly to end of open label therapy]
Quantification of Human Betaretrovirus DNA or RNA levels in peripheral blood measured by Quantigene or polymerase chain reaction with therapy or placebo.
- Interferon gamma release to Human Betaretrovirus peptide stimulation [Evaluation at baseline, 6 months and end of RCT; then 6 monthly to end of open label therapy]
Concentration of interferon gamma released from peripheral blood mononuclear cells stimulated by Human Betaretrovirus peptides in vitro in response to treatment or placebo.
- Liver histology [Pretreatment biopsy and 24 month biopsy after initiation of study therapy]
Liver histology will be measured in a scale for staging and grading disease using the Nakanuma scoring system. Scores for fibrosis, bile duct loss, and chronic cholestasis will be combined for staging: stage 1, total score of 0; stage 2, score 1-3; stage 3, score 4-6; and stage 4, score 7-9. Cholangitis activity and hepatitis activity will be graded as 0-3, respectively.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
over 18 years old of either sex,
-
Anti-mitochondrial antibody +ve or liver histology compatible with PBC,
-
stable UDCA dose of 13-15 mg/kg for > 12 months or intolerant to UDCA,
-
ALP at least 1.67 x ULN or abnormal bilirubin less than 2x ULN
-
able to read and sign informed consent form.
Exclusion Criteria:
-
subjects with baseline total bilirubin > 2 x ULN,(patients meeting inclusion criteria stabilized on second line therapies including obeticholic acid or bezafibrate over 12 months or more may be enrolled).
-
use of non-standard or experimental therapy within the last 6 months,
-
advanced liver disease: INR > 1.2 ULN, Albumin < 35 g/L lower limit of normal, platelets < 120,000/microL unless varices with risk of bleeding excluded by endoscopy within the last 6 months, Childs Pugh class B or C cirrhosis, presence of grade 2 varices or previous variceal hemorrhage, encephalopathy, ascites or need for liver transplantation within the next two years;
-
secondary diagnosis such as HIV, viral hepatitis, drug induced liver injury, extrahepatic biliary obstruction, primary sclerosing cholangitis, metabolic liver - regular use of > 30g alcohol/day in the last year;
-
a predicted survival of less than 3 years from malignant or other life threatening disease;
-
hepatic mass consistent with hepatocellular carcinoma ;
-
previous allergic reaction to study medications;
-
Glomerular Filtration Rate less than < 30 mL/min as measured Cockcroft-Gault formula;
-
pregnancy, breast-feeding or pre-menopausal patients not using contraception.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Alberta | Edmonton | Alberta | Canada | T6G 2R3 |
| 2 | St Paul's Hospital, University of British Columbia | Vancouver | British Columbia | Canada | V6Z 1Y6 |
| 3 | Vancouver General Hospital, University of Brittish Columbia | Vancouver | British Columbia | Canada | V6Z 1Z4 |
| 4 | University of Toronto | Toronto | Ontario | Canada | M5S 1A1 |
| 5 | University of Montreal | Montréal | Quebec | Canada | |
| 6 | Royal University Hospital | Saskatoon | Saskatchewan | Canada | S7N 0W8 |
Sponsors and Collaborators
- University of Alberta
- Merck Sharp & Dohme LLC
Investigators
- Principal Investigator: Andrew Mason, MD, University of Alberta
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Pro00082571